secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001600620-24-000106
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q3 net product rev $55.5M (+36% YoY), net income $14.4M; restructuring cuts 45% workforce
--------------------------------------------------------------------------------

- Q3 total net revenue $67.8M; net product revenue $55.5M (+36% YoY); net income $14.4M vs loss of $13.4M a year ago.
- Strategic restructuring: workforce reduction ~45%, expects annual cash savings >$40M, one-time Q4 charge $15-19M.
- FY2024 net product revenue guidance reiterated $210-220M; YTD net product revenue $158.6M.
- AUR200 Phase 1 first participant dosed; initial results expected H1 2025.
- Board: Craig Johnson appointed, Dr. Robert Foster retired (not due to disagreement).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/auph-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001600620-24-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer